Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia

Archive ouverte

Fayol, Antoine | Livrozet, Marine | Pereira, Héléna | Diehl, Jean-Luc | Lebeaux, David | Arlet, Jean-Benoit | Cholley, Bernard | Carette, Claire | Carves, Jean-Baptiste | Czernichow, Sébastien | Hauw, Caroline | Hamada, Sophie-Rym | Jannot, Anne-Sophie | Volle, Geoffroy | Masurkar, Nihar | Mirault, Tristan | Planquette, Benjamin | Sanchez, Olivier | Châtellier, Gilles | Azizi, Michel | Hulot, Jean-Sébastien

Edité par CCSD ; MDPI -

International audience. We aimed to compare the influence of cardiometabolic disorders on the incidence of severe COVID-19 vs. non-COVID pneumonia. We included all consecutive patients admitted with SARS-CoV-2-positive pneumonia between 12 March 2020 and 1 April 2020 and compared them to patients with influenza pneumonia hospitalized between December 2017 and December 2019 at the same tertiary hospital in Paris. Patients with COVID-19 were significantly younger and more frequently male. In the analysis adjusted for age and sex, patients with COVID-19 were more likely to be obese (adjOR: 2.25; 95% CI 1.24–4.09; p = 0.0076) and receive diuretics (adjOR: 2.13; 95% CI 1.12–4.03; p = 0.021) but were less likely to be smokers (adjOR: 0.40; 95% CI 0.24–0.64; p = 0.0002), have COPD (adjOR: 0.25; 95% CI 0.11–0.56; p = 0.0008), or have a previous or active cancer diagnosis (adjOR: 0.54, 95% CI 0.32–0.91; p = 0.020). The rate of ICU admission was significantly higher in patients with COVID-19 (32.4% vs. 5.2% p < 0.0001). Obesity was significantly associated with the risk of direct ICU admission in patients with COVID-19 but not in patients with influenza pneumonia. Likewise, pre-existing hypertension was significantly associated with mortality in patients with COVID-19 but not in patients with influenza pneumonia. Cardiometabolic disorders differentially influenced the risk of presenting with severe COVID-19 or influenza pneumonia.

Suggestions

Du même auteur

Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

Archive ouverte | Mariette, Xavier | CCSD

International audience

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Archive ouverte | Tharaux, Pierre-Louis | CCSD

International audience. Background: Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a...

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

Archive ouverte | Hermine, Olivier | CCSD

International audience. Importance Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19).Objective To determine whether tocilizumab (TCZ...

Chargement des enrichissements...